De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study

BACKGROUND: In human epidermal growth factor receptor 2 (HER2+) breast cancers, neoadjuvant trials of chemotherapy plus anti-HER2 treatment consistently showed lower pathologic complete response (pCR) rates in hormone receptor (HR) positive versus negative tumors. The PerELISA study was aimed to eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Guarneri, V, Dieci, M V, Bisagni, G, Frassoldati, A, Bianchi, G V, De Salvo, G L, Orvieto, E, Urso, L, Pascual, T, Paré, L, Galván, P, Ambroggi, M, Giorgi, C A, Moretti, G, Griguolo, G, Vicini, R, Prat, A, Conte, P F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594455/
https://www.ncbi.nlm.nih.gov/pubmed/30778520
http://dx.doi.org/10.1093/annonc/mdz055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594455/
https://www.ncbi.nlm.nih.gov/pubmed/30778520
http://dx.doi.org/10.1093/annonc/mdz055

Ejemplares similares